**Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event**

**reporting system (FAERS)**

Victor Pera PharmD1\*, Guy. G. Brusselle MD, PhD2,3, Sebastian Riemann MD2, Jan A. Kors PhD1, Erik M. van Mulligen PhD1, Rowan Parry PhD1, Marcel de Wilde BSc1, Peter R. Rijnbeek PhD1, Katia M.C. Verhamme MD, PhD1

1 Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

2 Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium

3 Departments of Epidemiology and Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

**\*Correspondence**

Victor Pera

[v.pera@erasmusmc.nl](mailto:v.pera@erasmusmc.nl)

Table S1. Preferred terms from the Medical Dictionary for Regulatory Activities®, version 24.1, representing parasitic infections under the high level group term “Helminthic disorders” and “Infections - pathogen unspecified”. NEC = Not elsewhere classified

|  |  |  |
| --- | --- | --- |
| **Code** | **Preferred Term** | **High Level Term** |
| 10069517 | Angiostrongylus infection | Nematode infections |
| 10002533 | Anisakiasis | Nematode infections |
| 10060967 | Arthritis helminthic | Helminthic infections NEC |
| 10003442 | Ascariasis | Nematode infections |
| 10065200 | Biliary tract infection helminthic | Helminthic infections NEC |
| 10007187 | Capillariasis | Nematode infections |
| 10061039 | Cestode infection | Cestode infections |
| 10009344 | Clonorchiasis | Trematode infections |
| 10059547 | Cutaneous larva migrans | Nematode infections |
| 10065199 | Cystitis helminthic | Helminthic infections NEC |
| 10080485 | Dicrocoeliasis | Trematode infections |
| 10013029 | Diphyllobothriasis | Cestode infections |
| 10080486 | Dipylidiasis | Cestode infections |
| 10080290 | Dirofilariasis | Nematode infections |
| 10080496 | Disseminated strongyloidiasis | Nematode infections |
| 10013618 | Dracunculiasis | Nematode infections |
| 10014096 | Echinococciasis | Cestode infections |
| 10065327 | Endocarditis helminthic | Helminthic infections NEC |
| 10014881 | Enterobiasis | Nematode infections |
| 10065204 | Enterocolitis helminthic | Helminthic infections NEC |
| 10065180 | Eye infection helminthic | Helminthic infections NEC |
| 10016234 | Fascioliasis | Trematode infections |
| 10016235 | Fasciolopsiasis | Trematode infections |
| 10016674 | Filariasis | Nematode infections |
| 10016675 | Filariasis lymphatic | Nematode infections |
| 10065207 | Gastritis helminthic | Helminthic infections NEC |
| 10065223 | Genital infection helminthic | Helminthic infections NEC |
| 10018490 | Gnathostomiasis | Nematode infections |
| 10061201 | Helminthic infection | Helminthic infections NEC |
| 10019659 | Hepatic echinococciasis | Cestode infections |
| 10065216 | Hepatic infection helminthic | Helminthic infections NEC |
| 10020017 | Heterophyiasis | Trematode infections |
| 10020376 | Hookworm infection | Nematode infections |
| 10020546 | Hymenolepiasis | Cestode infections |
| 10021857 | Infection parasitic | Infections NEC |
| 10065210 | Lymphadenitis helminthic | Helminthic infections NEC |
| 10065171 | Meningoencephalitis helminthic | Helminthic infections NEC |
| 10027436 | Metagonimiasis | Trematode infections |
| 10065219 | Myocarditis helminthic | Helminthic infections NEC |
| 10062701 | Nematodiasis | Nematode infections |
| 10058443 | Neurocysticercosis | Cestode infections |
| 10030314 | Onchocerciasis | Nematode infections |

Table S1 continued

|  |  |  |
| --- | --- | --- |
| **Code** | **Preferred Term** | **High Level Term** |
| 10084319 | Onchodermatitis | Nematode infections |
| 10030897 | Opisthorchiasis | Trematode infections |
| 10065329 | Oral helminthic infection | Helminthic infections NEC |
| 10065189 | Pancreatitis helminthic | Helminthic infections NEC |
| 10033794 | Paragonimiasis | Trematode infections |
| 10069588 | Parasitic encephalitis | Infections NEC |
| 10067720 | Parasitic gastroenteritis | Infections NEC |
| 10056704 | Parasitic esophagitis | Infections NEC |
| 10078883 | Parasitic pneumonia | Infections NEC |
| 10065221 | Pericarditis helminthic | Helminthic infections NEC |
| 10065326 | Peritonitis helminthic | Helminthic infections NEC |
| 10065246 | Pneumonia helminthic | Helminthic infections NEC |
| 10037374 | Pulmonary echinococciasis | Cestode infections |
| 10078264 | Renal echinococciasis | Cestode infections |
| 10039603 | Schistosomiasis | Trematode infections |
| 10039605 | Schistosomiasis bladder | Trematode infections |
| 10039606 | Schistosomiasis cutaneous | Trematode infections |
| 10039610 | Schistosomiasis liver | Trematode infections |
| 10065172 | Skin infection helminthic | Helminthic infections NEC |
| 10065193 | Splenic infection helminthic | Helminthic infections NEC |
| 10042254 | Strongyloidiasis | Nematode infections |
| 10080487 | Syngamiasis | Nematode infections |
| 10043095 | Taeniasis | Cestode infections |
| 10043720 | Thyroid echinococciasis | Cestode infections |
| 10044269 | Toxocariasis | Nematode infections |
| 10061859 | Trematode infection | Trematode infections |
| 10044608 | Trichiniasis | Nematode infections |
| 10044627 | Trichostrongyliasis | Nematode infections |
| 10044630 | Trichuriasis | Nematode infections |
| 10065258 | Tropical eosinophilia | Nematode infections |
| 10065186 | Upper respiratory tract infection helminthic | Helminthic infections NEC |
| 10065328 | Vulvovaginitis helminthic | Helminthic infections NEC |
| 10065243 | Wound infection helminthic | Helminthic infections NEC |

Table S2. Reference numbers for case reports describing the use of i) omalizumab, dupilumab, mepolizumab, benralizumab or reslizumab and ii) describing a parasitic infection, accompanied by a description of indication, type of parasitic infection and year with quarter. †From the legacy adverse event reporting system database

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Report id** | **Drug** | **Indication** | **Parasitic Infection** | **Report year** | **Quarter** | **Reporter** | **Country** |
| 6412861† | Omalizumab | Unknown | Infection Parasitic | 2009 | Q4 | Other health-professional | United States |
| 6422338† | Omalizumab | Unknown | Infection Parasitic | 2009 | Q4 | Physician | United States |
| 7456124† | Omalizumab | Asthma | Taeniasis | 2011 | Q2 | Physician | Italy |
| 7831160† | Omalizumab | Asthma | Helminthic Infection | 2011 | Q4 | Physician | United Kingdom |
| 88868233 | Omalizumab | Asthma | Hepatic echinococciasis | 2013 | Q2 | Other health-professional | Unknown |
| 112279541 | Omalizumab | Unknown | Infection parasitic | 2015 | Q2 | Other health-professional | United States |
| 116713721 | Omalizumab | Unknown | Infection parasitic | 2015 | Q4 | Consumer | United States |
| 120462742 | Omalizumab | Unknown | Infection parasitic | 2016 | Q1 | Physician | United States |
| 127270233 | Omalizumab | Unknown | Infection parasitic | 2017 | Q2 | Other health-professional | United States |
| 128327562 | Mepolizumab | Unknown | Infection parasitic | 2016 | Q4 | Consumer | United States |
| 130536502 | Omalizumab | Unknown | Infection parasitic | 2017 | Q1 | Physician | Canada |
| 133047542 | Omalizumab | Urticaria Chronic | Diphyllobothriasis | 2017 | Q2 | Physician | Denmark |
| 135297952 | Omalizumab | Asthma | Enterobiasis | 2017 | Q2 | Physician | United States |
| 135384151 | Omalizumab | Asthma | Strongyloidiasis | 2017 | Q2 | Physician | Spain |
| 135833931 | Omalizumab | Unknown | Infection parasitic | 2017 | Q2 | Consumer | Netherlands |
| 135951192 | Omalizumab | Chronic Spontaneous Urticaria | Opisthorchiasis | 2017 | Q3 | Physician | Russian Federation |
| 152438235 | Dupilumab | Unknown | Infection parasitic | 2018 | Q4 | Physician | United States |
| 153768121 | Omalizumab | Unknown | Infection parasitic | 2018 | Q3 | Consumer | United States |
| 154171474 | Benralizumab | Unknown | Infection parasitic | 2019 | Q2 | Physician | United States |
| 155437031 | Mepolizumab | Unknown | Strongyloidiasis | 2018 | Q4 | Other health-professional | Australia |
| 155446756 | Omalizumab | Asthma | Arthritis helminthic | 2019 | Q3 | Consumer | Brazil |
| 156369229 | Dupilumab | Dermatitis Atopic | Helminthic infection | 2020 | Q3 | Consumer | United States |
| 159035971 | Benralizumab | Asthma | Enterobiasis | 2019 | Q1 | Physician | United States |
| 159198241 | Omalizumab | Unknown | Infection parasitic | 2019 | Q1 | Physician | United States |
| 159279334 | Benralizumab | Asthma | Infection parasitic | 2019 | Q2 | Unknown | United States |
| 159279334 | Benralizumab | Asthma | Strongyloidiasis | 2019 | Q2 | Unknown | United States |
| 159385621 | Omalizumab | Unknown | Infection parasitic | 2019 | Q1 | Consumer | United States |
| 159385621 | Omalizumab | Unknown | Enterobiasis | 2019 | Q1 | Consumer | United States |
| 159389361 | Omalizumab | Unknown | Enterobiasis | 2019 | Q1 | Consumer | United States |
| 160665231 | Mepolizumab | Unknown | Infection parasitic | 2019 | Q1 | Consumer | Canada |
| 160926871 | Benralizumab | Unknown | Infection parasitic | 2019 | Q1 | Consumer | United States |
| 161733721 | Benralizumab | Asthma | Helminthic infection | 2019 | Q2 | Physician | United States |

Table S2 continued

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Report id** | **Drug** | **Indication** | **Parasitic Infection** | **Report year** | **Quarter** | **Reporter** | **Country** |
| 162228012 | Mepolizumab | Unknown | Enterobiasis | 2019 | Q2 | Consumer | United States |
| 162231351 | Dupilumab | Unknown | Infection parasitic | 2019 | Q2 | Physician | United States |
| 163153155 | Dupilumab | Asthma | Enterobiasis | 2020 | Q2 | Consumer | United States |
| 164557632 | Mepolizumab | Asthma | Helminthic infection | 2019 | Q3 | Consumer | United States |
| 164821131 | Dupilumab | Unknown | Infection parasitic | 2019 | Q2 | Consumer | United States |
| 165259972 | Mepolizumab | Unknown | Infection parasitic | 2019 | Q4 | Consumer | United States |
| 165380635 | Dupilumab | Dermatitis Atopic | Helminthic infection | 2020 | Q4 | Consumer | United States |
| 165871631 | Dupilumab | Unknown | Infection parasitic | 2019 | Q3 | Consumer | United States |
| 166135231 | Omalizumab | Unknown | Infection parasitic | 2019 | Q3 | Physician | Peru |
| 166854971 | Dupilumab | Unknown | Infection parasitic | 2019 | Q3 | Consumer | United States |
| 168228951 | Mepolizumab | Unknown | Parasitic gastroenteritis | 2019 | Q3 | Consumer | Slovakia |
| 169536901 | Dupilumab | Asthma | Helminthic infection | 2019 | Q4 | Consumer | United States |
| 169750711 | Dupilumab | Unknown | Infection parasitic | 2019 | Q4 | Consumer | United States |
| 170932051 | Mepolizumab | Unknown | Strongyloidiasis | 2019 | Q4 | Consumer | United States |
| 173246732 | Omalizumab | Asthma | Enterobiasis | 2020 | Q4 | Consumer | Canada |
| 175066951 | Omalizumab | Unknown | Infection parasitic | 2020 | Q1 | Consumer | United States |
| 175440962 | Omalizumab | Unknown | Parasitic gastroenteritis | 2020 | Q2 | Physician | Uruguay |
| 176897311 | Dupilumab | Unknown | Helminthic infection | 2020 | Q2 | Consumer | United States |
| 177316141 | Benralizumab | Eosinophil Count Increased | Enterobiasis | 2020 | Q2 | Consumer | United States |
| 178661361 | Dupilumab | Unknown | Cestode infection | 2020 | Q2 | Pharmacist | Germany |
| 178773361 | Benralizumab | Asthma | Trichuriasis | 2020 | Q2 | Physician | United States |
| 181342151 | Mepolizumab | Unknown | Helminthic infection | 2020 | Q3 | Consumer | United Kingdom |
| 181359671 | Mepolizumab | Unknown | Helminthic infection | 2020 | Q3 | Consumer | United Kingdom |
| 182472141 | Mepolizumab | Unknown | Infection parasitic | 2020 | Q3 | Consumer | United States |
| 182565491 | Dupilumab | Dermatitis | Enterobiasis | 2020 | Q3 | Consumer | United States |
| 182811391 | Dupilumab | Unknown | Infection parasitic | 2020 | Q3 | Unknown | United States |
| 183252511 | Benralizumab | Unknown | Helminthic infection | 2020 | Q3 | Unknown | United States |
| 183524341 | Dupilumab | Unknown | Helminthic infection | 2020 | Q4 | Consumer | United States |
| 184553801 | Dupilumab | Unknown | Infection parasitic | 2020 | Q4 | Consumer | United States |
| 187547381 | Dupilumab | Unknown | Parasitic gastroenteritis | 2021 | Q1 | Consumer | United States |
| 188900731 | Dupilumab | Unknown | Infection parasitic | 2021 | Q1 | Consumer | United States |
| 189987444 | Dupilumab | Dermatitis | Enterobiasis | 2021 | Q4 | Physician | United States |
| 190275381 | Dupilumab | Unknown | Helminthic infection | 2021 | Q1 | Physician | United States |
| 190772101 | Dupilumab | Unknown | Enterobiasis | 2021 | Q1 | Consumer | United States |
| 191667251 | Dupilumab | Neurodermatitis | Helminthic infection | 2021 | Q2 | Consumer | Germany |
| 192436002 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |
| 192538592 | Dupilumab | Nasal Polyps | Nematodiasis | 2021 | Q3 | Consumer | United States |
| 194491684 | Dupilumab | Dermatitis Atopic | Helminthic infection | 2021 | Q4 | Physician | United States |
| 194749502 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |

Table S2 continued

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Report id** | **Drug** | **Indication** | **Parasitic Infection** | **Report year** | **Quarter** | **Reporter** | **Country** |
| 195031201 | Benralizumab | Unknown | Echinococciasis | 2021 | Q3 | Physician | Germany |
| 195420921 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |
| 196135061 | Mepolizumab | Unknown | Parasitic pneumonia | 2021 | Q3 | Consumer | Austria |
| 196159612 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |
| 197404401 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |
| 199016991 | Dupilumab | Unknown | Infection parasitic | 2021 | Q3 | Consumer | United States |
| 199162231 | Dupilumab | Unknown | Infection parasitic | 2021 | Q4 | Physician | United States |
| 199611801 | Dupilumab | Dermatitis Atopic | Helminthic infection | 2021 | Q4 | Physician | United States |
| 201822031 | Dupilumab | Unknown | Enterobiasis | 2021 | Q4 | Physician | United States |
| 201925381 | Dupilumab | Dermatitis Atopic | Helminthic infection | 2021 | Q4 | Physician | United States |

Table S3. Raw data on the occurrence of the parasitic infection, start/end date of the therapy, and calculated time of onset based on available data. Dates are expressed in YYYYMMDD where YYYY=Year, MM=Month, and DD=Day. †From the legacy adverse event reporting system database

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Report id** | **Drug** | **Date of parasitic infection** | **Start of therapy** | **End date of therapy** | **Time to onset (days)** |
| 6412861† | Omalizumab |  |  |  |  |
| 6422338† | Omalizumab |  |  |  |  |
| 7456124† | Omalizumab | 20110406 | 20110330 |  | -24 |
| 7831160† | Omalizumab | 20110522 | 20110413 |  | 9 |
| 88868233 | Omalizumab |  |  |  |  |
| 112279541 | Omalizumab |  |  |  |  |
| 116713721 | Omalizumab |  |  |  |  |
| 120462742 | Omalizumab |  |  |  |  |
| 127270233 | Omalizumab | 20160329 | 20160329 | 20160824 | 0 |
| 128327562 | Mepolizumab | 20160930 | 2016 |  |  |
| 130536502 | Omalizumab | 20161214 | 20160809 |  | 5 |
| 133047542 | Omalizumab | 20160601 | 20160111 |  | -10 |
| 135297952 | Omalizumab | 200910 | 200909 |  |  |
| 135384151 | Omalizumab | 20150526 | 20130730 |  | -4 |
| 135833931 | Omalizumab |  |  |  |  |
| 135951192 | Omalizumab | 201705 | 201705 |  |  |
| 152438235 | Dupilumab | 20180227 | 20161220 | 20161220 | 7 |
| 153768121 | Omalizumab |  |  |  |  |
| 154171474 | Benralizumab | 20180512 | 20180411 |  | 1 |
| 155437031 | Mepolizumab |  |  |  |  |
| 155446756 | Omalizumab | 20180812 | 20180912 |  | 0 |
| 156369229 | Dupilumab | 201901 | 20181115 |  |  |
| 159035971 | Benralizumab |  |  |  |  |
| 159198241 | Omalizumab |  |  |  |  |
| 159279334 | Benralizumab | 201812 | 2018 |  |  |
| 159385621 | Omalizumab | 20181114 | 201807 |  |  |
| 159389361 | Omalizumab |  |  |  |  |
| 160665231 | Mepolizumab |  |  |  |  |
| 160926871 | Benralizumab |  |  |  |  |
| 161733721 | Benralizumab |  |  |  |  |
| 162228012 | Mepolizumab |  |  |  |  |
| 162231351 | Dupilumab |  |  |  |  |
| 163153155 | Dupilumab | 20190426 | 20190426 | 20190426 | 0 |
| 164557632 | Mepolizumab | 201812 | 20160113 |  |  |
| 164821131 | Dupilumab | 201905 | 20170501 |  |  |
| 165259972 | Mepolizumab |  |  |  |  |
| 165380635 | Dupilumab | 2020 | 20190322 | 20201029 |  |
| 165871631 | Dupilumab |  | 20190610 |  |  |
| 166135231 | Omalizumab | 2016 | 201511 | 20160407 |  |

Table S3 continued

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Report id** | **Drug** | **Date of parasitic infection** | **Start of therapy** | **End date of therapy** | **Time to onset (days)** |
| 166854971 | Dupilumab | 20190704 |  |  |  |
| 168228951 | Mepolizumab | 201908 |  |  |  |
| 169536901 | Dupilumab |  |  |  |  |
| 169750711 | Dupilumab | 2019 | 2019 |  |  |
| 170932051 | Mepolizumab |  |  |  |  |
| 173246732 | Omalizumab | 20180227 | 20180227 |  | 0 |
| 175066951 | Omalizumab |  |  |  |  |
| 175440962 | Omalizumab | 20200220 | 201906 |  |  |
| 176897311 | Dupilumab | 202003 | 20200220 |  |  |
| 177316141 | Benralizumab |  | 202001 |  |  |
| 178661361 | Dupilumab |  |  |  |  |
| 178773361 | Benralizumab |  | 20200129 |  |  |
| 181342151 | Mepolizumab |  |  |  |  |
| 181359671 | Mepolizumab |  |  |  |  |
| 182472141 | Mepolizumab | 2020 |  |  |  |
| 182565491 | Dupilumab | 2020 | 202004 |  |  |
| 182811391 | Dupilumab |  |  |  |  |
| 183252511 | Benralizumab | 2020 | 20200824 |  |  |
| 183524341 | Dupilumab | 2020 | 202007 |  |  |
| 184553801 | Dupilumab |  | 20190919 |  |  |
| 187547381 | Dupilumab |  | 20190606 |  |  |
| 188900731 | Dupilumab |  | 20201210 |  |  |
| 189987444 | Dupilumab | 20210212 | 20210212 |  | 0 |
| 190275381 | Dupilumab |  |  |  |  |
| 190772101 | Dupilumab | 20210325 |  |  |  |
| 191667251 | Dupilumab |  | 2021 |  |  |
| 192436002 | Dupilumab | 20210503 | 20180731 |  | -28 |
| 192538592 | Dupilumab | 20210406 | 20200211 | 20210408 | -5 |
| 194491684 | Dupilumab |  | 20210525 | 20211005 |  |
| 194749502 | Dupilumab | 2020 | 2020 |  |  |
| 195031201 | Benralizumab |  |  |  |  |
| 195420921 | Dupilumab | 20210222 | 202011 |  |  |
| 196135061 | Mepolizumab |  |  |  |  |
| 196159612 | Dupilumab |  |  |  |  |
| 197404401 | Dupilumab |  | 202004 |  |  |
| 199016991 | Dupilumab | 20210927 | 20201212 |  | 15 |
| 199162231 | Dupilumab | 20210901 | 202012 |  |  |
| 199611801 | Dupilumab | 20190101 | 20191101 | 20191101 | 0 |
| 201822031 | Dupilumab |  | 20210216 |  |  |
| 201925381 | Dupilumab | 20210101 | 20210525 | 20210525 | -24 |

Table S4. Primary disproportionality analysis, in which “other-drug” represents all other drugs in FAERS. “Event” represents a parasitic infection. Counts A,B,C and D correspond with counts as presented in manuscript Table 1.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **ATC** | **Drug-event count (A)** | **Drug-other event count (B)** | **Other drug-event count (C)** | **Other drug-other event count (D)** | **ROR**  **(95% CI)** |
| Omalizumab | R03DX05 | 25 | 149,272 | 1,597 | 37,368,549 | 3.9  (2.6 - 5.8) |
| Dupilumab | D11AH05 | 34 | 201,181 | 1,588 | 37,316,640 | 4.0  (2.8 - 5.6) |
| Mepolizumab | R03DX09 | 12 | 47,270 | 1,610 | 37,470,551 | 5.9  (3.4 - 10.4) |
| Benralizumab | R03DX10 | 10 | 14,807 | 1,612 | 37,503,014 | 15.7  (8.4 - 29.3) |
| Reslizumab | R03DX08 | 0 | 997 | 1,622 | 37,516,824 | NA |

ATC = Anatomical Therapeutic Chemical classification, NA = Not Applicable, ROR= Reporting Odds Ratio, 95% CI = 95% Confidence Interval

Table S5. 1st secondary disproportionality analysis, in which “other-drug” represents all other drugs in FAERS, excluding all drugs under ATC level 5 “P”. “Event” represents a parasitic infection. Counts A,B,C† and D† correspond with counts as presented in manuscript Table 1.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **ATC** | **Drug-event count (A)** | **Drug-other event count (B)** | **Other drug-event count (C†)** | **Other drug-other event count (D†)** | **ROR**  **(95% CI)** |
| Omalizumab | R03DX05 | 25 | 149,272 | 1,443 | 37,267,467 | 4.3  (2.9 - 6.4) |
| Dupilumab | D11AH05 | 34 | 201,181 | 1,434 | 37,215,558 | 4.4  (3.1 - 6.2) |
| Mepolizumab | R03DX09 | 12 | 47,270 | 1,456 | 37,369,469 | 6.5  (3.7 - 11.5) |
| Benralizumab | R03DX10 | 10 | 14,807 | 1,458 | 37,401,932 | 17.3  (9.3 - 32.3) |
| Reslizumab | R03DX08 | 0 | 997 | 1,468 | 37,415,742 | NA |

ATC = Anatomical Therapeutic Chemical classification, NA = Not Applicable, ATC code “P” = Antiparasitic products, insecticides and repellents, ROR= Reporting Odds Ratio, 95% CI = 95% Confidence Interval

Table S6. 2nd secondary disproportionality analysis, in which “other-drug” represents the other biologics in this table. “Event” represents a parasitic infection. Counts A,B,C‡ and D‡ correspond with counts as presented in manuscript Table 1.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **ATC** | **Drug-event count (A)** | **Drug-other event count (B)** | **Other drug-event count (C**‡**)** | **Other drug-other event count (D**‡**)** | **ROR**  **(95% CI)** |
| Dupilumab | D11AH05 | 34 | 201,181 | 47 | 212,346 | 0.8  (0.5 - 1.2) |
| Omalizumab | R03DX05 | 25 | 149,272 | 56 | 264,255 | 0.8  (0.5 - 1.3) |
| Mepolizumab | R03DX09 | 12 | 47,270 | 69 | 366,257 | 1.4  (0.7 - 2.5) |
| Benralizumab | R03DX10 | 10 | 14,807 | 71 | 398,720 | 3.8  (2.0 - 7.4) |
| Reslizumab | R03DX08 | 0 | 997 | 81 | 412,530 | NA |

ATC = Anatomical Therapeutic Chemical classification, NA = Not Applicable, ROR= Reporting Odds Ratio, 95% CI = 95% Confidence Interval